• Facebook
  • Twitter
  • Instagram
  • YouTube
Skip to content
METUPUK

METUPUK

Dying For A Cure

Donate Now
  • Home
  • #DarkerPink
    • WHO REALLY CARES?
    • #DarkerPink Exhibition
    • #DarkerPink TV ad 2022
  • About us
    • Welcome to METUPUK
    • Who are we? Our Mission Statement
    • Why are we doing this?
    • Red flag #SBCinfographic
    • International Allies – The ABC Global Alliance
    • Our friends not forgotten
    • METUPUK Strategy
    • METUPUK – around the UK
      • MBC Wales
        • MBC Wales – About Us
        • MBC Wales – The Gammon Dragon
      • MBC Scotland (coming soon)
      • MBC N.I. (coming soon)
  • Aims & Objectives
    • Awareness & Education
    • Research & Access to drugs
    • Patient Treatment and Care
  • Research & Trials
    • Clinical trials
    • Treatment Lines
    • METUPUKs #TrodelvyNow Campaign
  • Help us
    • Resources
    • I Am The 31
    • METUPUK Newsletter
    • Join us
  • News/Blog
METUPUK

METUPUK

Donate Now
  • Home
  • #DarkerPink
    • WHO REALLY CARES?
    • #DarkerPink Exhibition
    • #DarkerPink TV ad 2022
  • About us
    • Welcome to METUPUK
    • Who are we? Our Mission Statement
    • Why are we doing this?
    • Red flag #SBCinfographic
    • International Allies – The ABC Global Alliance
    • Our friends not forgotten
    • METUPUK Strategy
    • METUPUK – around the UK
      • MBC Wales
        • MBC Wales – About Us
        • MBC Wales – The Gammon Dragon
      • MBC Scotland (coming soon)
      • MBC N.I. (coming soon)
  • Aims & Objectives
    • Awareness & Education
    • Research & Access to drugs
    • Patient Treatment and Care
  • Research & Trials
    • Clinical trials
    • Treatment Lines
    • METUPUKs #TrodelvyNow Campaign
  • Help us
    • Resources
    • I Am The 31
    • METUPUK Newsletter
    • Join us
  • News/Blog

Month: February 2022

Home > 2022 > February

Tucatinib is approved by NICE for HER2+ metastatic breast cancer

February 23, 2022March 7, 2022 metupuk
TUKYSA-tucatinib

METUPUK welcome the National Institute of Clinical Excellence (NICE) decision to accept Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies for routine commissioning use in NHS in England and Wales.

Patient Advocacy, Policy, Treatment Options

Why did Jo Taylor our Founder create the infographics?

February 4, 2022February 25, 2022 metupuk

Before I was diagnosed with metastatic breast cancer (also called secondary / advanced / stage 4 breast cancer) I was aware that there was a huge lack of awareness of

continue reading
Uncategorized

Follow us on the Socials

Get involved and help make a difference:

Facebook
Twitter
Instagram

Latest tweets

Tweets by @metupukorg

METUPUK Strategy Doc

METUPUK Volunteer Agreement

METUPUK Conflict of Interest

Follow us on socials

  • Facebook
  • Twitter
  • Instagram
  • YouTube

Latest from the News/Blog

  • How do we get better outcomes and survival for Metastatic Breast Cancer? February 2, 2025
  • Trustees’ Week by Madeleine Meynell November 6, 2024
  • Why I volunteer with METUPUK… October 30, 2024
  • I’m a 51 year old NHS nurse and 18 months ago I was told i had MBC… October 29, 2024
  • I remember the 22nd April 2021 very clearly… October 28, 2024
Copyright MET UP UK © Charity number 1196494. All right reserved.